Herman O. Sintim
Immunology and Microbiology · Purdue University West Lafayette
Publications
265
Citations
7,841
Est. group size
~19
Recurring co-author estimate
Active years
23
Publishing since 2004
Herman O. Sintim's research focuses on the chemistry and biology of cyclic dinucleotides and related signaling molecules, including their role in bacterial and immune signaling pathways such as cGAS-STING. His group also develops small-molecule inhibitors targeting enzymes involved in cancer (such as RET and kinase pathways), bacterial resistance, and inflammation, working at the interface of chemical biology, medicinal chemistry, and microbiology.
Publication output has fluctuated over the last decade with a notable spike in 2023, followed by a return to a steady average of roughly 16 papers per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Structural and biochemical insights into the inhibition of <i>Mycobacterium tuberculosis</i> cyclic dinucleotide phosphodiesterase by a sulfur-modified cyclic dinucleotide analog
RSC Chemical Biology · 2026
- 2-Morpholino-substituted imidazothiadiazole TAK1 inhibitors for reduction of proinflammatory cytokines
European Journal of Medicinal Chemistry Reports · 2026
- Inhibitors of Cyclic Dinucleotide Phosphodiesterases and Cyclic Oligonucleotide Ring Nucleases as Potential Drugs for Various Diseases
Cells · 2025
- Morpholino nicotinamide analogs of ponatinib, dual MNK, p70S6K inhibitors, display efficacy against lung and breast cancers
Bioorganic Chemistry · 2025
- 5′-Phosphorothioester Linked Cyclic Dinucleotides, Endo-S-CDNs, Displaying Impressive Antitumor Activities In Vivo when Dosed Subcutaneously
ACS Bio & Med Chem Au · 2025
- 3H-pyrazolo[4,3-f]quinoline hinge binder, a tunable scaffold for development of novel kinase inhibitors against FLT3-driven leukemia
European Journal of Medicinal Chemistry · 2025
- Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy
RSC Medicinal Chemistry · 2025
- Abstract 1658 Use of a red fluorescent small molecule for real-time tracking of cyclic di-nucleotide production and degradation by c-di-AMP cyclase and phosphodiesterase enzymes
Journal of Biological Chemistry · 2025
- P04 HSD 1624 as an adjuvant of colistin for MDR bacteria
JAC-Antimicrobial Resistance · 2025
- Supplementary Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
2025
- Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors
European Journal of Medicinal Chemistry · 2024
- PDE-stable 2′3′-cGAMP analogues, containing 5′-S-phosphorothioester linkage, as STING agonists
RSC Medicinal Chemistry · 2024
- 2’,4’‐LNA‐Functionalized 5′‐S‐Phosphorothioester CDNs as STING Agonists
ChemBioChem · 2024
- Boronic Acid-Containing 3H- pyrazolo[4,3-f]quinoline Compounds as Dual CLK/ROCK Inhibitors with Anticancer Properties
Pharmaceuticals · 2024
- Activation of cellular responses by cyclic dinucleotides and <i>Porphyromonas gingivalis</i> lipopolysaccharide: a proteomic study on gingival fibroblasts
Journal of Oral Microbiology · 2024
- RSC Medicinal Chemistry×7
- European Journal of Medicinal Chemistry×6
- Chemical Communications×5
- Journal of Medicinal Chemistry×5
- Future Medicinal Chemistry×4
- Blaise R. Kimmel
Immunology and Microbiology · The Ohio State University
- Adriana Forero
Immunology and Microbiology · The Ohio State University
- Ajit Elhance
Immunology and Microbiology · The Ohio State University
- Adam D. Kenney
Immunology and Microbiology · The Ohio State University
- Ashley Zani
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile